HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

Blood

Volumn 109, Issue 8, 2007, Pages 3351-3359

  Boasso, Adriano ^a   Herbeuval, Jean Philippe ^a,b   Hardy, Andrew W ^a   Anderson, Stephanie A ^c   Dolan, Matthew J ^c   Fuchs, Dietmar ^d   Shearer, Gene M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CNRS   (France)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL TRYPTOPHAN; CD28 ANTIGEN; CD3 ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; MESSENGER RNA; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME INDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

EID: 34147115208     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-034785     Document Type: Article

References (64)

1. Dickmeiss E. Immunology of the human immunodeficiency virus infection. Tokai J Exp Clin Med. 1990;15:263-267.
2. Mendila M, Heiken H, Becker S, et al. Immunologic and virologic studies in long-term nonprogressors with HIV-1 infection. Eur J Med Res. 1999;4:417-424.
3. Casseb JS, Benard G, Saito R, et al. The value of the lymphocyte proliferation test with phytohemagglutinin in the immune evaluation of Brazilian HIV-infected patients. J Investig Allergol Clin Immunol. 1995;5:347-349.
4. Janossy G, Borthwick N, Lomnitzer R, et al. Lymphocyte activation in HIV-1 infection, I: predominant proliferative defects among CD45R0+ cells of the CD4 and CD8 lineages. Aids. 1993;7:613-624.
5. Hofmann B, Nishanian P, Baldwin RL, Insixiengmay P, Nel A, Fahey JL. HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism. J Immunol. 1990;145:3699-3705.
6. Rosenberg E. Backgrounder: recognizing and diagnosing primary HIV infection. Res Initiat Treat Action. 2002;7:5-10.
7. Krowka J, Stites D, Debs R, et al. Lymphocyte proliferative responses to soluble and liposome-conjugated envelope peptides of HIV-1. J Immunol. 1990;144:2535-2540.
8. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol. 1987;61:2017-2023.
9. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients: independence of CD4+ cell numbers and clinical staging. J Clin Invest. 1989;84:1892-1899.
10. Dolan MJ, Clerici M, Blatt SP, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis. 1995;172:79-87.
11. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774.
12. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;129:186-196.
13. Grohmann U, Fallarino F, Bianchi R, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med. 2003;198:153-160.
14. Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101:151-155.
15. Kudo Y, Boyd CA. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim Biophys Acta. 2000;1500:119-124.
16. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193.
17. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633-642.
18. Fuchs D, Forsman A, Hagberg L, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res. 1990;10:599-603.
19. Murray MF. Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect Dis. 2003;3:644-652.
20. Grant RS, Naif H, Thuruthyil SJ, et al. Induction of indoleamine 2,3-dioxygenase in primary human macrophages by HIV-1. Redox Rep. 2000;5:105-107.
21. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum kynurenine-totryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem. 1998;44:858-862.
22. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res. 2005;7:103-123.
23. Kerr SJ, Armati PJ, Pemberton LA, Smythe G, Tattam B, Brew BJ. Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology. 1997;49:1671-1681.
24. Potula R, Poluektova L, Knipe B, et al. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood. 2005;106:2382-2390.
25. Andersson J, Boasso A, Nilsson J, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. 2005;174:3143-3147.
26. Nilsson J, Boasso A, Velilla PA, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. Prepublished on August 10, 2006, as DOI 10.1182/blood-2006-05- 021576. (Now available as Blood. 2006;108:3808-3817.)
27. Estes JD, Li Q, Reynolds MR, et al. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis. 2006;193:703-712.
28. Rossio JL, Esser MT, Suryanarayana K, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998;72:7992-8001.
29. Arthur LO, Bess JW Jr, Chertova EN, et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses. 1998;14(suppl 3):S311-S319.
30. Chertova E, Crise BJ, Morcock DR, Bess JW Jr, Henderson LE, Lifson JD. Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins. Curr Mol Med. 2003;3:265-272.
31. Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology. 1997;230:134-144.
32. Wang CY, Sawyer LS, Murthy KK, et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci U S A. 1999;96:10367-10372.
33. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997;43:2424-2426.
34. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002;168:3771-3776.
35. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol. 2005;175:5601-5605.
36. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3:1097-1101.
37. Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood. 2005;105:1574-1581.
38. Fallarino F, Orabona C, Vacca C, et al. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int Immunol. 2005;17:1429-1438.
39. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280-290.
40. Herbeuval JP, Hardy AW, Boasso A, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A. 2005;102:13974-13979.
41. Herbeuval JP, Grivel JC, Boasso A, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood. 2005;106:3524-3531.
42. Frolova LY, Grigorieva AY, Sudomoina MA, Kisselev LL. The human gene encoding tryptophanyl-tRNA synthetase: interferon-response elements and exon-intron organization. Gene. 1993;128:237-245.
43. Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol. 2002;104:242-247.
44. Werner ER, Fuchs D, Hausen A, et al. Tryptophan degradation in patients infected by human immunodeficiency virus. Biol Chem Hoppe Seyler. 1988;369:337-340.
45. Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? a review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood. 2001;98:1667-1677.
46. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol. 2000;74:7320-7330.
47. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203:2281-2292.
48. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350-354.
49. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198-1202.
50. Weber WP, Feder-Mengus C, Chiarugi A, et al. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2006;36:296-304.
51. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor {zeta}-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752-6761.
52. Zhang R, Lifson JD, Chougnet C. Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions. Blood. 2006;107:1989-1995.
53. Herbeuval JP, Nilsson J, Boasso A, et al. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A. 2006;103:7000-7005.
54. Herbeuval JP, Boasso A, Grivel JC, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood. 2005;105:2458-2464.
55. Fitzgerald W, Sylwester AW, Grivel JC, Lifson JD, Margolis LB. Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo. J Virol. 2004;78:7061-7068.
56. Fonteneau JF, Larsson M, Beignon AS, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol. 2004;78:5223-5232.
57. Hryniewicz A, Boasso A, Edghill-Smith Y, et al. CTLA-4 blockade decreases TGF-β-, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Prepublished on August 8, 2006, as DOI 10.1182/blood-2006-04-010637. (Now available as Blood. 2006;108:3834-3842.)
58. Baban B, Hansen AM, Chandler PR, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol. 2005;17:909-919.
59. Schmidt B, Fujimura SH, Martin JN, Levy JA. Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol. 2006;26:55-64.
60. Herbeuval JP, Shearer GM. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis? AIDS Rev. 2006;8:3-8.
61. Conti L, Fantuzzi L, Del Corno M, Belardelli F, Gessani S. Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: implications for AIDS pathogenesis. Immunobiology. 2004;209:99-115.
62. Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun. 2005;338:20-24.
63. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med. 2004;10:15-18.
64. Wahren B, Liu M. Therapeutic vaccination against HIV. Expert Rev Vaccines. 2004;3:S179-S188.